
Smruthi Organics (SMRUTHIORG) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
380.9M
Gross Profit
157.9M
41.45%
Operating Income
31.7M
8.33%
Net Income
22.3M
5.85%
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
401.1M
Shareholders Equity
716.3M
Debt to Equity
0.56
Cash Flow Metrics
Revenue & Profitability Trend
Smruthi Organics Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 1.3B | 1.3B | 1.4B | 1.3B | 1.2B |
Cost of Goods Sold | 686.0M | 749.0M | 937.5M | 821.6M | 683.3M |
Gross Profit | 574.0M | 519.9M | 468.8M | 507.5M | 559.6M |
Gross Margin % | 45.6% | 41.0% | 33.3% | 38.2% | 45.0% |
Operating Expenses | |||||
Research & Development | - | 9.1M | 5.7M | 6.6M | 4.0M |
Selling, General & Administrative | - | 21.8M | 13.1M | 11.1M | 8.6M |
Other Operating Expenses | 278.7M | 205.3M | 198.0M | 172.9M | 165.8M |
Total Operating Expenses | 278.7M | 236.2M | 216.8M | 190.6M | 178.5M |
Operating Income | 66.8M | 63.0M | 52.1M | 141.7M | 245.9M |
Operating Margin % | 5.3% | 5.0% | 3.7% | 10.7% | 19.8% |
Non-Operating Items | |||||
Interest Income | - | 671.0K | 874.0K | 5.8M | 4.9M |
Interest Expense | 18.7M | 10.1M | 3.8M | 4.8M | 6.5M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 49.0M | 49.7M | 44.9M | 137.7M | 240.6M |
Income Tax | 13.4M | 13.8M | 3.6M | 33.9M | 69.5M |
Effective Tax Rate % | 27.3% | 27.8% | 8.1% | 24.6% | 28.9% |
Net Income | 35.6M | 35.9M | 41.3M | 103.8M | 171.1M |
Net Margin % | 2.8% | 2.8% | 2.9% | 7.8% | 13.8% |
Key Metrics | |||||
EBITDA | 122.7M | 116.3M | 94.4M | 185.0M | 286.5M |
EPS (Basic) | - | ₹3.14 | ₹3.61 | ₹9.07 | ₹14.95 |
EPS (Diluted) | - | ₹3.14 | ₹3.61 | ₹9.07 | ₹14.95 |
Basic Shares Outstanding | - | 11446000 | 11446000 | 11446000 | 11443101 |
Diluted Shares Outstanding | - | 11446000 | 11446000 | 11446000 | 11443101 |
Income Statement Trend
Smruthi Organics Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 4.4M | 4.8M | 5.9M | 2.4M | 161.4M |
Short-term Investments | 1.8M | 1.5M | 11.6M | 3.2M | - |
Accounts Receivable | 324.7M | 410.3M | 369.6M | 285.0M | 213.5M |
Inventory | 283.1M | 297.8M | 239.9M | 199.3M | 181.3M |
Other Current Assets | 19.2M | -1.0K | -1.0K | -1.0K | - |
Total Current Assets | 633.3M | 754.2M | 653.0M | 525.0M | 590.8M |
Non-Current Assets | |||||
Property, Plant & Equipment | 448.1M | 106.7M | 96.6M | 91.2M | 85.3M |
Goodwill | 1.6M | 1.7M | 834.0K | 209.0K | 234.4K |
Intangible Assets | 1.6M | 1.7M | 834.0K | 209.0K | 234.4K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 63.0K | 2.0K | 4.0K | -2.0K | 7.8M |
Total Non-Current Assets | 484.1M | 427.7M | 403.4M | 351.1M | 327.4M |
Total Assets | 1.1B | 1.2B | 1.1B | 876.1M | 918.2M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 159.9M | 286.4M | 246.6M | 110.6M | 140.0M |
Short-term Debt | 86.7M | 62.5M | 51.1M | 27.2M | 99.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 3.7M | 499.0K | 20.6M | -1.0K | 18.5M |
Total Current Liabilities | 310.8M | 420.6M | 354.8M | 156.0M | 261.3M |
Non-Current Liabilities | |||||
Long-term Debt | 81.3M | 56.5M | 5.9M | 1.1M | 5.0M |
Deferred Tax Liabilities | 8.8M | 8.6M | 10.4M | 20.6M | 22.3M |
Other Non-Current Liabilities | - | - | 1.0M | 1 | 24.7M |
Total Non-Current Liabilities | 90.4M | 65.1M | 20.1M | 48.5M | 52.0M |
Total Liabilities | 401.1M | 485.7M | 374.8M | 204.5M | 313.3M |
Equity | |||||
Common Stock | 114.5M | 114.5M | 114.5M | 114.5M | 114.5M |
Retained Earnings | - | 569.4M | 554.8M | 544.8M | 478.1M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 716.3M | 696.2M | 681.6M | 671.6M | 604.9M |
Key Metrics | |||||
Total Debt | 168.0M | 119.0M | 57.0M | 28.2M | 104.2M |
Working Capital | 322.6M | 333.6M | 298.3M | 369.0M | 329.5M |
Balance Sheet Composition
Smruthi Organics Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 51.1M | 51.8M | 48.7M | 137.7M | 240.6M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 126.0M | -105.2M | -110.5M | -76.7M | 78.3M |
Operating Cash Flow | 195.1M | -43.3M | -54.4M | 65.0M | 324.2M |
Investing Activities | |||||
Capital Expenditures | -115.2M | -82.4M | -94.7M | -65.5M | -39.0M |
Acquisitions | - | - | - | - | - |
Investment Purchases | 0 | - | -8.4M | 0 | 0 |
Investment Sales | 230.0K | - | - | 127.9M | - |
Investing Cash Flow | -114.9M | -82.4M | -103.1M | 62.4M | -39.6M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -17.2M | -22.9M | -34.3M | -34.3M | - |
Debt Issuance | 52.5M | 67.4M | 8.7M | 0 | 0 |
Debt Repayment | -16.8M | -6.7M | -2.4M | -77.1M | -57.6M |
Financing Cash Flow | 33.8M | 33.7M | -7.0M | -185.0M | -111.7M |
Free Cash Flow | -15.4M | -38.4M | 26.4M | -43.8M | 189.3M |
Net Change in Cash | 113.9M | -92.0M | -164.5M | -57.6M | 172.9M |
Cash Flow Trend
Smruthi Organics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
38.73
Price to Book
1.93
Price to Sales
1.10
Profitability Ratios
Profit Margin
2.83%
Operating Margin
8.33%
Return on Equity
5.05%
Return on Assets
3.63%
Financial Health
Current Ratio
2.04
Debt to Equity
23.65
Beta
-0.12
Per Share Data
EPS (TTM)
₹3.12
Book Value per Share
₹62.58
Revenue per Share
₹110.09
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
smruthiorg | 1.4B | 38.73 | 1.93 | 5.05% | 2.83% | 23.65 |
Sun Pharmaceutical | 3.9T | 37.88 | 5.45 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.42 | 10.88 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 45.5B | -13.34 | -21.04 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 44.4B | 23.59 | 3.25 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 43.9B | 154.18 | 6.24 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.